Last reviewed · How we verify
NCT05109130
Change of Circulating Tumor Cells During Laparoscopic or Transanal Endoscopic Surgery for Rectal Cancer.
trial testing Surgical approach in Rectal Neoplasms in 100 participants. Status unknown.
25 October 2022
Quick facts
| Lead sponsor | Sun Yat-sen University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 100 |
| Start date | 18 October 2021 |
| Primary completion | 25 October 2022 |
| Estimated completion | 18 October 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Surgical approach
Conditions studied
- Rectal Neoplasms — all drugs for Rectal Neoplasms →
- Neoplastic Cells, Circulating — all drugs for Neoplastic Cells, Circulating →
- Laparoscopic Surgery — all drugs for Laparoscopic Surgery →
- Transanal Endoscopic Surgery — all drugs for Transanal Endoscopic Surgery →
Sponsor
Sun Yat-sen University
Who can join
18 and older, any sex, with Rectal Neoplasms or Neoplastic Cells, Circulating. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The primary purpose of this study is to compare the changes of circulating tumor cells (CTCs) at different time points in rectal cancer patients undergoing laparoscopic or transanal endoscopic radical resection. Our secondary purpose is to explore the effects of perioperative circulating tumor cells on tumor recurrence and metastasis.
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Janjua D, Chaudhary A, Joshi U, Tripathi T, et al · · 2025 · cited 4× · PMID 40676582 · DOI 10.1186/s12935-025-03883-y -
Changes to circulating tumor cells in the central vein during laparoscopic versus transanal endoscopic surgeries for rectal cancer: can surgical approach make a difference?
· 2024 -
Changes to circulating tumor cells in the central vein during laparoscopic versus transanal endoscopic surgeries for rectal cancer: can surgical approach make a difference?
Chen M, Ye F, Zheng W, Xiong L, et al · · 2024 · PMID 38939193 · DOI 10.1093/gastro/goae062
Verify or expand the search:
- PubMed search for NCT05109130
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Surgical approach
Trials testing the same drug.
- NCT07189780 — Comparison of Different Surgical Approaches in Female Rectal Cancer. · NA · not yet recruiting
- NCT03344484 — Midline Versus Paramedian Approaches in Treating Degenerative Lumbar Spondylolisthesis · NA · recruiting
- NCT04438226 — Surgical Approach of Hemiarthroplasty After Femoral Neck Fracture: Posterolateral or Direct Lateral · NA · completed
- NCT07267767 — Comparison of Six Different Machine Learning Methods With Traditional Model for Low Anterior Resection Syndrome After Mi · completed
Other recruiting trials for Rectal Neoplasms
Currently open trials in the same condition.
- NCT07522294 — Optimization and Standardization of Single-Port Robotic Transanal Minimally Invasive Surgery for Rectal Tumor Excision · NA · active not recruiting
- NCT07154173 — Comprehensive Analysis of Gut Microbiota Signatures in Metastatic Colorectal Cancer · recruiting
- NCT06442215 — Selection of Surgical Technique in Rectal Cancer · recruiting
- NCT06017583 — Neoadjuvant Chemotherapy With PD-1 Inhibitors Combined With SIB-IMRT in the Treatment of Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT05943444 — Comparison of Postoperative Anal Function Between Parks and Bacon Techniques in Low Rectal Cancer · NA · recruiting
Other Sun Yat-sen University trials
Trials by the same sponsor.
- NCT07255612 — Bone Marrow Protection, Safety, Efficacy of Trilaciclib and Eribulin in Locally Advanced or Metastatic TNBC(Triple-negat · Phase 2 · not yet recruiting
- NCT07371897 — Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial · Phase 3 · not yet recruiting
- NCT07489703 — SHR-A1811 + AK112 in HER2-Altered Advanced/Metastatic NSCLC · Phase 2 · not yet recruiting
- NCT07528209 — Neoadjuvant CAPOX With or Without Pucotenlimab Plus Selective Radiotherapy for Locally Advanced Rectal Cancer · Phase 3 · recruiting
- NCT07522281 — Evaluation of an Undisturbed Embryo Culture System for Embryo Development in IVF/ICSI Cycles · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05109130 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sun Yat-sen University
- Last refreshed: 13 April 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05109130.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing